- Home
- MDXG
MDXG
MiMedx Group Inc
as 07-26-2024 4:00pm EST
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Upcoming Earnings Alert:
Get ready for potential market movements as MiMedx Group Inc MDXG prepares to release earnings report on 31 Jul 2024.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | MARIETTA |
| Market Cap: | 1.1B | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 643.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.57 - $9.27 | Next Earning Date: | 07-31-2024 |
| Revenue: | $334,510,000 | Revenue Growth: | 19.20% |
| Revenue Growth (this year): | 14.7% | Revenue Growth (next year): | 12.36% |
Stock Insider Trading Activity of MiMedx Group Inc (MDXG)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hulse William Frank IV | MDXG | General Counsel and CAO | Mar 13 '24 | Sell | $7.95 | 20,381 | $162,028.95 | 479,959 | SEC Form 4 |
| Whitlow Ricci S | MDXG | Chief Operating Officer | Feb 16 '24 | Sell | $8.07 | 15,493 | $125,074.99 | 416,321 | SEC Form 4 |
| Whitlow Ricci S | MDXG | Chief Operating Officer | Feb 16 '24 | Sell | $8.01 | 15,271 | $122,351.25 | 401,050 | SEC Form 4 |
| Whitlow Ricci S | MDXG | Chief Operating Officer | Feb 14 '24 | Sell | $8.06 | 15,198 | $122,495.88 | 431,814 | SEC Form 4 |
| Whitlow Ricci S | MDXG | Chief Operating Officer | Feb 14 '24 | Sell | $8.03 | 15,845 | $127,267.04 | 447,012 | SEC Form 4 |
| DOUG RICE | MDXG | Chief Financial Officer | Nov 21 '23 | Buy | $7.16 | 5,000 | $35,786.50 | 102,200 | SEC Form 4 |
Latest MiMedx Group Inc News
MDXG Breaking Stock News: Dive into MDXG Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
GlobeNewswire
10 days ago
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
GlobeNewswire
10 days ago
MIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31
MT Newswires
25 days ago
--Cantor Fitzgerald Initiates MiMedx at Overweight Rating With $11 Price Target
MT Newswires
a month ago
MiMedx Group Promotes Kim Moller to Chief Commercial Officer
GlobeNewswire
a month ago
MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer
Simply Wall St.
a month ago
With 45% ownership, MiMedx Group, Inc. (NASDAQ:MDXG) has piqued the interest of institutional investors
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
Compare MDXG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDXG MiMedx Group Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.